AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns

Increased risks of death have led three groups of oncology drugmakers to withdraw their PARP inhibitors in heavily pretreated ovarian cancer patients.

In a decision that has largely flown under the radar, AstraZeneca and Merck & Co. have started pulling Lynparza’s approval in BRCA-mutated advanced ovarian cancer patients who have received at least three prior lines of chemotherapy.